10-Q: Cardinal Health Reports Strong Q2 FY26 Growth Driven by Acquisitions

Cardinal Health announced robust financial results for Q2 fiscal year 2026, with significant revenue and earnings growth fueled by strategic acquisitions and strong performance across its segments.

Summary

• Revenue for the three months ended December 31, 2025, increased 19% to $65.6 billion, and for the six months, it rose 21% to $129.6 billion, primarily due to branded and specialty pharmaceutical sales growth.
• GAAP operating earnings for the three months increased 29% to $707 million, and for the six months, it increased 23% to $1.4 billion.
• Non-GAAP operating earnings for both the three and six months increased 38% to $877 million and $1.7 billion, respectively.
• GAAP diluted EPS for the three months increased 19% to $1.97, and for the six months, it increased 15% to $3.85.
• Non-GAAP diluted EPS for both the three and six months increased 36% to $2.63 and $5.18, respectively.
• The Pharmaceutical and Specialty Solutions (Pharma) segment revenue grew 19% to $60.7 billion for the three months and 21% to $119.9 billion for the six months.
• The Global Medical Products and Distribution (GMPD) segment revenue increased 3% to $3.3 billion for the three months and $6.4 billion for the six months.
• Other segment revenue, including at-Home Solutions and Nuclear and Precision Health Solutions, increased 34% to $1.7 billion for the three months and 36% to $3.4 billion for the six months.
• Gross margin for the three months increased 23% to $2.4 billion, and for the six months, it increased 23% to $4.7 billion, with gross margin rates improving by 14 basis points and 7 basis points, respectively.
• The acquisition of Solaris Health, a urology MSO, was completed on November 3, 2025, for approximately $1.9 billion in cash, increasing ownership in The Specialty Alliance to approximately 76%.
• Increased demand for GLP-1 pharmaceuticals significantly impacted Pharma segment and consolidated revenue, though it did not meaningfully contribute to segment profit.
• Net cash provided by operating activities for the six months ended December 31, 2025, was $1.7 billion, including $403 million in opioid litigation payments.
• The company deployed $1.9 billion for the Solaris Health acquisition, $758 million for share repurchases, and $251 million for dividends during the six-month period.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, reflecting robust financial growth driven by strategic acquisitions and effective operational management, despite increased interest expenses and ongoing litigation costs.

Positives

• Overall revenue growth of 19% for the quarter and 21% for the six months demonstrates strong market demand and successful customer acquisition.
• Significant increases in GAAP operating earnings (+29% for the quarter) and Non-GAAP operating earnings (+38% for the quarter) highlight improved operational efficiency and profitability.
• Diluted EPS (GAAP +19%, Non-GAAP +36% for the quarter) shows enhanced shareholder value.
• The Pharma segment exhibited robust revenue growth (+19% for the quarter) and profit growth (+29% for the quarter), driven by branded and specialty pharmaceuticals and MSO acquisitions.
• The GMPD segment's profit increased significantly due to growth from existing customers and cost optimization initiatives.
• The 'Other' segment, including at-Home Solutions and OptiFreight Logistics, showed strong revenue (+34% for the quarter) and profit growth (+52% for the quarter).
• Strategic acquisitions of MSO platforms (Solaris Health, GIA, Urology America, ION) are positively impacting segment profit and expanding service offerings.
• The generics program positively impacted Pharma segment profit, indicating effective management of this key area.
• Successful resolution of the New York Opioid Stewardship Act challenge resulted in a $17 million gain.
• Received $19 million in net recoveries from class action antitrust litigation.

Negatives

• Cash and equivalents decreased to $2.8 billion at December 31, 2025, from $3.9 billion at June 30, 2025, primarily due to acquisition funding and share repurchases.
• Interest expense, net, significantly increased to $88 million for the three months and $168 million for the six months, primarily due to additional debt financing for recent acquisitions.
• Increased GLP-1 pharmaceutical sales, while boosting revenue, did not meaningfully contribute to segment profit, indicating lower margins on these high-demand products.
• Gross margin rates, while up, were partially offset by the unfavorable changes in product mix for the Pharma segment, driven by increased pharmaceutical distribution branded sales which have a dilutive impact.
• Acquisition-related cash and share-based compensation costs were $67 million for the three months and $131 million for the six months, impacting GAAP operating earnings.

Risks

• Competitive pressures in the markets, including pricing pressures, could impact future profitability.
• Uncertainties relating to the pricing of and demand for generic pharmaceuticals, as well as the timing, frequency, magnitude, and profit impact of generic pharmaceutical launches, customer volumes, and pricing changes.
• Recently imposed or threatened U.S. tariffs and retaliatory actions could result in substantial additional costs, supply disruptions, or shortages, and the company may not be able to fully mitigate these impacts through price increases or alternative sourcing.
• Future demand for GLP-1 medications is unpredictable, and the ability to meet demand may be impacted by supply constraints.
• The Executive Order titled 'Delivering Most-Favored Nation Prescription Drug Pricing to American Patients' may impact sales or profitability of branded pharmaceutical products, with uncertain extent and timeline.
• The ability to successfully provide physician practice support and management services and to receive expected value from MSO acquisitions depends on factors like recruitment and retention of providers, alignment of interests, successful negotiations with vendors/payors, and the regulatory environment.
• Any compromise of information systems or those of third-party service providers, including unauthorized access or data breaches, could disrupt operations or lead to disclosure of sensitive information.
• Continuing risks associated with the resolution and defense of opioid lawsuits and investigations, including compliance with the National Opioid Settlement Agreement (NOSA) and potential penalties for non-compliance.
• An unfavorable outcome in ongoing insurance litigation related to opioid matters could negatively impact cash flow.
• The Department of Justice Civil Investigative Demand regarding potential Anti-Kickback Statute and False Claims Act violations could lead to claims or sanctions.
• The ongoing legal proceedings related to Cordis IVC filter products, despite settlements, still carry accrued losses and defense costs.
• The IRS Notice of Proposed Adjustment related to a 2017 acquisition could create additional federal income tax liability of approximately $160 million, plus interest.
• Modification of certain finance and operating information systems in the Pharma segment, if not effectively implemented or if they fail to operate as intended, could adversely affect internal control over financial reporting.
• Goodwill and intangible assets could become impaired, leading to significant charges to earnings, especially for recent acquisitions where minimal excess of estimated fair value over carrying value is expected.

Future Outlook

The company anticipates continued growth from its MSO platforms and branded/specialty pharmaceutical products. However, future demand for GLP-1 pharmaceuticals is unpredictable, and supply constraints may impact the ability to meet demand. The Executive Order on Most-Favored Nation Prescription Drug Pricing may impact future sales or profitability, with the extent of impact being uncertain. The company expects to make the majority of its remaining opioid litigation settlement payments through 2038. The IRS NOPA related to a prior restructuring could create additional federal income tax liability, which the company intends to defend against.

Management Comments

• Management believes that, based on available capital resources and projected operating cash flow, the company has adequate capital resources to fund operations and expected future cash needs.
• Management notes that the ability to successfully provide physician practice support and management services, and to receive the value expected from recent MSO platform acquisitions, depends on various factors including recruitment, integration, retention of providers, and the regulatory environment.

Industry Context

StockSavvy.ai notes that Cardinal Health's strong performance in its Pharma segment, particularly with branded and specialty pharmaceuticals, aligns with broader industry trends of increasing demand for specialized and high-value medications, including GLP-1 drugs. The strategic focus on acquiring and integrating Management Services Organization (MSO) platforms like Solaris Health, GI Alliance, and Integrated Oncology Network positions Cardinal Health to capitalize on the growing trend of physician practice consolidation and value-based care models. The company's ability to navigate tariff impacts and manage generic pharmaceutical programs effectively demonstrates resilience in a dynamic healthcare supply chain environment. The ongoing opioid litigation and regulatory scrutiny remain significant industry-wide challenges, requiring substantial financial and operational resources.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Accrued $4.3 billion at December 31, 2025, for opioid-related matters, with $403 million paid during the six months ended December 31, 2025.
• The National Opioid Settlement Agreement (NOSA) resolves the vast majority of lawsuits by states and political subdivisions, with expected payments up to $4.1 billion through 2038.
• Settled opioid-related claims with the majority of remaining West Virginia subdivisions for approximately $124 million and Native American Tribes for approximately $136 million.
• A judgment in favor of the Distributors in the Cabell County and City of Huntington opioid case was vacated by the Fourth Circuit in October 2025 and remanded for further proceedings, with a hearing scheduled for March 2026.
• Approximately 193 lawsuits by private plaintiffs (including ~51 purported class actions) related to opioids are pending, with the company vigorously defending itself.
• Finalized agreements with classes of third-party payors and acute care hospitals for opioid settlements, with Cardinal Health's portion totaling $213 million.
• Involved in lawsuits with insurers regarding their obligations to reimburse for defense and indemnity costs in opioid litigation, with a hearing scheduled for February 5, 2026.
• Received $5 million in insurance recoveries related to opioid matters during the six months ended December 31, 2025.
• Received a Civil Investigative Demand (CID) from the Department of Justice in November 2023, focusing on potential Anti-Kickback Statute and False Claims Act violations related to a 2022 transaction.
• Accrued $36 million for losses and legal defense costs related to Cordis IVC filter product liability lawsuits, following a $275 million settlement for approximately 4,375 claims in April 2023.
• Recognized a $17 million gain in December 2025 from a final settlement related to the New York Opioid Stewardship Act.
• Recognized $19 million in income for net recoveries in class action antitrust litigation during both the three and six months ended December 31, 2025.
• Received a Notice of Proposed Adjustment (NOPA) from the IRS on February 2, 2026, asserting a potential additional federal income tax liability of approximately $160 million, plus interest, related to a 2017 restructuring.

Related Party Transactions

• Aircraft Time Sharing Agreement, effective November 18, 2025, between Cardinal Health, Inc. and Jason M. Hollar (CEO), for personal use of company aircraft. User pays for direct operating costs plus 100% of fuel, oil, lubricants, and other additives, and applicable Federal Excise Taxes.
• Red Oak Sourcing, LLC, a U.S.-based generic pharmaceutical sourcing venture with CVS Health Corporation, for which Cardinal Health is required to make quarterly payments to CVS Health for the term of the arrangement, extended through June 2029.

Stakeholder Impact

• Shareholders benefit from increased diluted EPS and ongoing share repurchase programs, but face potential dilution from acquisition-related share-based compensation and risks from increased debt and litigation.
• Employees may be impacted by restructuring and employee severance costs related to cost-savings measures and manufacturing rationalization.
• Customers benefit from expanded services through MSO acquisitions and potentially from supply chain efficiencies, but may face price increases due to tariffs.
• Creditors are impacted by the increase in long-term obligations, though the company remains in compliance with its net leverage ratio covenant.
• Physicians and management of acquired MSOs receive common units in The Specialty Alliance, aligning their interests with Cardinal Health's growth.

Next Steps

• Continue to integrate acquired MSO platforms (Solaris Health, GIA, Urology America, ION) to realize expected value and synergies.
• Monitor and respond to the unpredictable demand and potential supply constraints for GLP-1 pharmaceuticals.
• Evaluate and adapt to the potential impacts of the Executive Order on Most-Favored Nation Prescription Drug Pricing.
• Vigorously defend against the remanded Cabell County and City of Huntington opioid case, with a hearing scheduled for March 2026.
• Participate in the insurance litigation hearing related to opioid matters scheduled for February 5, 2026.
• Cooperate with the Department of Justice investigation regarding the Civil Investigative Demand.
• Address the IRS Notice of Proposed Adjustment related to the FY15-FY20 audit cycle and defend the company's tax positions.
• Continue to implement enterprise-wide cost-savings measures and initiatives to rationalize manufacturing operations.
• Complete the valuation analysis and purchase price allocation for recent acquisitions (Solaris Health, Urology America, ADS, GIA).

Key Dates

Recommendation

The filing demonstrates strong financial performance with significant revenue and earnings growth across all segments, driven by successful strategic acquisitions in the MSO space. While increased interest expense and ongoing litigation present challenges, the company's ability to integrate new businesses, manage its generics program effectively, and generate substantial operating cash flow indicates a robust underlying business. The positive growth trajectory and strategic expansion outweigh the identified risks, suggesting a favorable outlook for long-term investors.

Keywords

Healthcare Services, Pharmaceutical Distribution, Medical Products, MSO Platforms, Acquisitions, Opioid Litigation, GLP-1, Generics Program, Supply Chain, Tariffs, Financial Performance, EPS, Revenue Growth